Pharmacokinetics, safety, and immunogenicity comparison of Bmab1700 and Opdivo® as adjuvant monotherapy in patients with melanoma

2025-525158-20-00 Protocol BIO-NIVOLU-103 Human pharmacology (Phase I) - First administration to humans Authorised, recruitment pending

Status Authorised, recruitment pending · 2 EU/EEA countries · 8 sites · Protocol BIO-NIVOLU-103

Overview

Sponsor-declared trial summary

Phase Human pharmacology (Phase I) - First administration to humans
Status Authorised, recruitment pending
Participants planned 120
Countries 2
Sites 8

Stage IIB/C, Stage III, or Stage IV Melanoma

Key facts

Sponsor
Biocon Biologics UK PLC
Participant type
Patients
Age range
18-64 years, 65+ years
Gender
Male and Female
Therapeutic area
Diseases [C] - Neoplasms [C04]
Decision date (initial)
2026-06-22
Transition trial
No
Low-intervention
No
Rare-disease indication
No
Vulnerable population
No

External identifiers

EU CT number
2025-525158-20-00
ClinicalTrials.gov
NCT07476326

Trial design

CTIS Part I — objectives, methods, condition coding

Conditions and MedDRA coding

Stage IIB/C, Stage III, or Stage IV Melanoma

Sponsors and contacts

Sponsor organisations, regulatory contacts, third parties

Biocon Biologics UK PLC

Sponsor organisation
Biocon Biologics UK PLC
Address
Covent Garden, 16 Great Queen Street 16 Great Queen Street
City
London
Postcode
WC2B 5AH
Country
United Kingdom

Scientific contact point

Organisation
Biocon Biologics UK PLC
Contact name
Dr. Dharma Rao Uppada, MD

Public contact point

Organisation
Biocon Biologics UK PLC
Contact name
Rajesh CN

Locations

2 EU/EEA countries · 8 investigational sites

By country

CountryMS statusPlanned subjectsSites
Romania Authorised, recruitment pending 15 1
Spain Authorised, recruitment pending 28 7
Rest of world
Serbia, Brazil, Turkey, Georgia, South Africa
77

Investigational sites

Romania

1 site · Authorised, recruitment pending
Centrul De Oncologie SF Nectarie S.R.L.
Medical Oncology, Strada Caracal Nr 109, 200542, Craiova

Spain

7 sites · Authorised, recruitment pending
Hospital Universitari Vall D Hebron
Oncology, Passeig De La Vall D'Hebron 119-129, 08035, Barcelona
University Clinical Hospital Virgen De La Arrixaca
Oncology, Carretera Madrid-Cartagena S/N, El Palmar, Murcia
Hospital Universitario Fundacion Jimenez Diaz
Oncology, Avenida De Los Reyes Catolicos 2, 28040, Madrid
Instituto Oncologico Dr. Rosell S.L.
Oncology, Calle De Sabino Arana Num. 5, 08028, Barcelona
University Hospital Virgen Del Rocio S.L.
Oncology, Avenida De Manuel Siurot S/n, 41013, Sevilla
Hospital Universitario Virgen De La Macarena
Oncology, Avenida Del Doctor Fedriani 3, 41009, Sevilla
Parc Tauli Hospital Universitari
Oncology, Parc Del Tauli 1, 08208, Sabadell

Application history

2 submissions — initial application plus substantial / non-substantial modifications

#TypeCodeSubmittedReference MSConclusionDecision date
1 INITIAL IN 2026-04-07 Spain Acceptable
2026-06-17
2026-06-22
2 NON SUBSTANTIAL MODIFICATION NSM-1 2026-07-01 Spain Acceptable
2026-06-17
2026-07-01